newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrollment Six Months